## Introduction
The question of who owns our bodies—and the cells, tissues, and genetic information derived from them—has become one of the most pressing challenges in modern medical law. As biotechnology accelerates our ability to isolate, analyze, and commercialize human biological materials, it creates a fundamental tension between personal autonomy, human dignity, and the pursuit of scientific progress. This article addresses the knowledge gap created by this rapid innovation, dissecting the complex legal frameworks that govern these invaluable resources.

This exploration will unfold across three distinct chapters. In "Principles and Mechanisms," we will lay the groundwork by examining the evolution of legal doctrine, from the common law's traditional "no-property" rule to the nuanced regulations governing [data privacy](@entry_id:263533) and intellectual property. Next, "Applications and Interdisciplinary Connections" will demonstrate how these principles are applied to resolve real-world disputes in tort law, patent ownership, criminal justice, and large-scale biobanking. Finally, "Hands-On Practices" will provide an opportunity to apply this knowledge to practical legal problems, honing your analytical skills on complex case scenarios. Together, these sections offer a comprehensive guide to navigating the legal and ethical landscape of property rights in the human body.

## Principles and Mechanisms

The legal and ethical status of human biological materials is one of the most complex and rapidly evolving areas of medical law. As biomedical science advances, our ability to separate, preserve, analyze, and transform human tissue and its constituent information grows, posing profound questions about ownership, control, and personhood. This chapter examines the core legal principles and mechanisms that govern property and related rights in human tissue and genetic information. We move from foundational common law rules to the intricate regulatory frameworks governing data, intellectual property, and the ethical limits of commodification.

### The Common Law Foundation: The “No-Property” Rule and Its Exception

The traditional starting point in common law jurisdictions is the principle that there is **no property in a human body**, whether living or dead. This rule is rooted in a fundamental distinction between persons, who are subjects of rights, and things (or chattels), which are objects of property rights. A corpse is not considered a chattel to be owned, bought, or sold; rather, the next of kin hold a limited, *sui generis* right to take possession for the purpose of a dignified burial.

However, this venerable rule is not absolute. An important exception, established over a century ago, holds that property rights can arise in separated body parts through the lawful application of **work and skill**. This principle, often traced back to the Australian case of *Doodeward v. Spence*, recognizes that when a person expends labor and expertise to alter a body part, giving it new attributes for a purpose such as scientific or educational display, the resulting object ceases to be a mere corpse and can become the subject of property rights. The property interest vests in the person who performed the work, not the original source of the tissue.

This “work and skill” exception is highly relevant in modern medicine and research. Consider a research hospital’s pathology museum that receives a post-mortem kidney donation. If the museum’s staff applies specialized techniques such as plastination, chemical fixation, and expert dissection to preserve the kidney as a permanent anatomical specimen for teaching, their effort transforms the organ from decaying biological matter into a durable, valuable artifact. Under the work and skill doctrine, the museum would likely acquire a proprietary or at least a possessory interest in this prepared specimen [@problem_id:4501828] [@problem_id:4501854].

The principle extends with even greater force to the creation of biological products through advanced biotechnology. If a company lawfully obtains a tissue sample—for instance, an excised tumor—and through considerable scientific investment and ingenuity, develops a stable, immortalized, and commercially valuable **cell line**, it has created something fundamentally new. This cell line, a product of human invention, is recognized as property belonging to the creating entity, entirely distinct from the original donated tissue [@problem_id:4501854].

### The Modern Challenge: Patient Rights and the *Moore* Doctrine

While the “work and skill” exception allows institutions to acquire property in transformed tissues, the question of whether the tissue source—the patient or donor—retains any property interest is more contentious. The landmark case that squarely addressed this issue in the age of biotechnology is *Moore v. Regents of the University of California*.

In that case, researchers developed a valuable cell line from Mr. Moore’s spleen cells without his knowledge of their commercial intent. Moore sued, claiming, among other things, the tort of **conversion**. Conversion is the wrongful exercise of ownership and control over another’s personal property. To succeed, Moore had to prove he had a continuing ownership interest in his excised cells. The California Supreme Court rejected this claim. It reasoned that to recognize a patient’s continuing property right in their excised cells would impose a host of problems on medical research, creating uncertain liability and difficult logistical burdens. The court held that once tissue is lawfully removed from the body, the patient no longer retains a property interest sufficient to support a claim for conversion [@problem_id:4501860] [@problem_id:4501828]. Similarly, a claim for **trespass to chattels**, which involves interference with another's possessory interest in personal property, would also fail for the same lack of a continuing proprietary interest.

The *Moore* decision, however, did not leave the patient without a remedy. The court found that the physicians had breached their fiduciary duty and the duty of informed consent by failing to disclose their personal financial and research interests. This highlights a crucial distinction: while a patient may not have a *property* claim, their rights are protected through the doctrines of **informed consent** and **fiduciary duty**.

Furthermore, some courts have left open the possibility of claims based on **unjust enrichment**. This is an equitable cause of action, not a property tort, which can be invoked when a defendant has been enriched at the plaintiff's expense under circumstances that make it unjust for the defendant to retain the benefit without compensation. Unlike conversion, a claim for unjust enrichment does not strictly require the plaintiff to have a formal property right. A court could potentially find that even if a research institution owns a cell line it developed, it has been unjustly enriched by profiting from the unique biological potential of a patient's cells without adequate compensation or disclosure, thereby providing a possible avenue for remedy where property claims fail [@problem_id:4501860].

### Nuanced Characterizations: The Importance of Control and Purpose

The legal status of separated tissue is not monolithic; it depends heavily on the context, particularly the purpose for which the tissue is stored and the control retained by the source individual. This is vividly illustrated by contrasting the *Moore* decision with the English case of *Yearworth v. North Bristol NHS Trust*. In *Yearworth*, several men had deposited sperm samples with a hospital for [cryopreservation](@entry_id:173046) before undergoing chemotherapy, with the clear intention of using the samples for their own future reproductive purposes [@problem_id:4501828]. When a freezer failure destroyed the samples, the men sued for negligence.

The Court of Appeal had to decide if the men had a legal interest in their sperm sufficient to ground their claim. Diverging from the broad rule in *Moore*, the court found that, for the purposes of claims in negligence and bailment, the men did have an ownership interest in their sperm. The court’s reasoning focused on the fact that the sperm was generated by their bodies, was stored for their exclusive benefit, and that they retained the power to direct its use and destruction. This degree of control was sufficient to characterize them as owners in this context.

This case introduces the legal concept of **bailment**, which is a relationship created when one person (the bailee) takes possession of a chattel owned by another (the bailor) for a specific purpose. For a bailment to exist, the bailor must have a property or immediate possessory interest in the object. The *Yearworth* court first had to establish the men's ownership of the sperm *before* it could conclude that the hospital was a bailee with corresponding duties of care. The case thus demonstrates that where tissue is stored for the direct and exclusive future use of the provider, courts may be willing to recognize a form of property right that they would deny in a research context like that of *Moore*.

### From Tangible Tissue to Intangible Information: Property vs. Consent

As technology has advanced, the focus of value has often shifted from the physical tissue sample to the intangible genetic information it contains. This shift requires us to move beyond traditional property law and engage with the distinct domain of information governance. Legal systems generally draw a sharp line between tangible objects, which can be property, and the intangible informational content about a person, which is regulated through privacy and data protection law [@problem_id:4501882].

This distinction can be clarified using a more formal analytical framework. We can differentiate between two primary mechanisms of governance: property-based control and consent-based authorization [@problem_id:4501830].

*   **Property-based control** is classically understood as a right *in rem*—a right enforceable against the world at large. Its core function is to allow an owner to exclude all others from a resource and to transfer that resource to others. If a donor transfers a tissue sample without reserving any rights, this transfer is typically final and cannot be unilaterally revoked. Any retained property right would, in theory, be enforceable against both the initial recipient and any downstream third parties.

*   **Consent-based authorization**, by contrast, creates rights *in personam*—rights that bind only the specific parties to the agreement (e.g., the donor and the research institution). Its function is not to grant ownership, but to grant permission, negating the wrongfulness of an act that would otherwise be a violation, such as the tort of battery or a breach of privacy. A key feature of consent in the medical and research context is that it is generally **prospectively revocable**; a donor can withdraw their permission for future uses of their tissue or data. However, this revocation does not invalidate past acts done with valid consent. Furthermore, its enforceability against third parties who receive materials from the original institution is not automatic and depends on the specific contracts and notices in place.

In most modern research scenarios, a donor's control over their genetic information is almost entirely governed by the latter framework. When a person donates tissue to a biobank, they are not retaining ownership of the future dataset. Instead, they are providing consent, which delineates the scope of permissible use for the institution. Their power lies in the right to withdraw that consent for future research and in the rights granted to them as a "data subject" under specific statutory regimes, such as the European Union’s General Data Protection Regulation (GDPR).

Under the GDPR, **genetic data** are considered **personal data**—and more specifically, a "special category" of personal data requiring heightened protection (Article 9). Even if direct identifiers like a name are removed, if the data can still be linked back to an individual via a code (a process known as **pseudonymization**), it remains personal data and falls under the full protection of the regulation. Truly **anonymized** data, where re-identification is not reasonably likely, falls outside the GDPR's scope. Therefore, a biobank's processing of pseudonymized genetic data is subject to strict conditions, including a valid legal basis (such as explicit consent or specific provisions for scientific research) and robust safeguards for the donor's rights [@problem_id:4501882].

### The Unique Nature of Genetic Information: Relationality and Externalities

Genetic information is unlike other forms of personal data, primarily because it is inherently relational. An individual's genome is not uniquely their own; it is shared by inheritance with their biological relatives. This creates profound social and ethical complexities that challenge traditional, individualistic notions of privacy and property.

From an information-theoretic and economic perspective, this shared nature can be described as a source of **relational externalities** [@problem_id:4501855]. The mutual information $I(G_A; G_B)$ between the genotype of Person A ($G_A$) and their full sibling Person B ($G_B$) is strictly positive, meaning that knowing $G_A$ reveals significant information about $G_B$. Consequently, when Person A decides to disclose their genetic sequence, perhaps for a fee, they impose a privacy risk on Person B and other relatives—an uncompensated external cost.

A simple property framework, where Person A has an exclusive, alienable right to their genome, fails to resolve this [externality](@entry_id:189875). While the Coase theorem suggests that if bargaining were costless, relatives could pay Person A not to disclose, the reality is that **transaction costs** are prohibitively high. Negotiating with a large, geographically dispersed family is impracticable, and the risk of **holdout** behavior (where individuals strategically delay agreement to extract more compensation) can derail any efficient bargain. A unilateral property right in the individual is therefore an inadequate mechanism for internalizing these familial spillovers [@problem_id:4501855].

This relational quality gives rise to the concept of **group privacy** [@problem_id:4501861]. This is the recognition that privacy interests related to genetics are not held solely by the individual but are shared by a collective, such as a family or an identifiable sub-population. This, in turn, creates **relational obligations** that may extend beyond the individual donor. For example, if a biobank discovers that a donor's DNA contains a variant for a serious, preventable condition like early-onset cardiomyopathy, an ethical and legal conflict arises. The donor's right to confidentiality conflicts with a potential duty to warn their biological relatives, who are at a foreseeable and substantial risk. Many ethical guidelines and legal frameworks now recognize that in such narrow circumstances, there may be a justification for a clinician to disclose limited, necessary information to at-risk relatives, even without the donor's consent, to prevent serious harm. This illustrates a profound shift from a purely individual model of control to one that acknowledges shared risks and duties.

### The Domain of Intellectual Property: Patenting Genetic Inventions

A distinct but related area of property rights concerns patents. A patent does not grant ownership of a physical thing, but rather the right to exclude others from making, using, or selling a claimed invention for a limited time. A central question in patent law is the distinction between a patent-ineligible **discovery** of something that already exists in nature and a patent-eligible **invention** created by human ingenuity [@problem_id:4501826].

This distinction was at the heart of the U.S. Supreme Court case *Association for Molecular Pathology v. Myriad Genetics*. The court ruled on the patent eligibility of human genes, making two critical findings:
1.  **Isolated genomic DNA (gDNA)** is **not patent-eligible**. The court reasoned that a claim on a segment of DNA with its native sequence, even when isolated from the chromosome, is directed to a "product of nature." The crucial information is the genetic sequence, which is not created by the person who isolates the gene.
2.  **Complementary DNA (cDNA)**, however, **is patent-eligible**. cDNA is a synthetic molecule created in a laboratory using reverse transcriptase. In this process, the non-coding regions of a gene ([introns](@entry_id:144362)) are removed, leaving only the coding regions (exons). Because this [intron](@entry_id:152563)-free structure does not exist in nature, cDNA is considered a human-made invention, not a discovery.

A similar logic applies to method patents, as clarified in *Mayo Collaborative Services v. Prometheus Laboratories*. A claim that is directed to a **law of nature**—such as the correlation between a drug metabolite level in the blood and a therapeutic outcome—is not patent-eligible unless it contains an "inventive concept." This means the claim must add "significantly more" to the natural law than simply stating it and adding steps that are well-understood, routine, and conventional. A method claim that merely instructs a doctor to measure a metabolite and adjust a drug dose based on a natural correlation, using standard techniques, is an unpatentable discovery of a natural law [@problem_id:4501826].

By contrast, a composition of matter that is truly a product of engineering, such as a viral vector containing a chimeric gene constructed from the sequences of two different species and linked to a synthetic promoter not found in nature, is clearly non-naturally occurring and represents a patentable invention [@problem_id:4501826].

### The Policy Frontier: Commodification, Dignity, and the Right to Science

The preceding discussions culminate in a broad and ongoing policy debate over the **commodification** of human biological materials—that is, the extent to which they can be treated as goods to be bought and sold in a market [@problem_id:4501843]. Legal systems around the world have adopted different approaches, creating a complex and often fragmented regulatory landscape.

In the United States, for example, there is a clear bifurcation. For certain renewable materials like blood plasma and gametes (sperm and eggs), compensated donation is generally permissible, regulated primarily under health and safety rules. In contrast, statutes like the National Organ Transplant Act (NOTA) expressly prohibit the transfer of solid human organs for "valuable consideration" for the purpose of transplantation. This legal divide reflects a policy judgment that while markets can be tolerated for some biologics, the sale of essential, non-renewable organs raises profound ethical concerns.

These prohibitions are often justified by appeals to fundamental principles of **human dignity** and **non-instrumentalization**, which are enshrined in international human rights instruments like the Council of Europe's Convention on Human Rights and Biomedicine (the "Oviedo Convention") [@problem_id:4501845]. The non-instrumentalization principle holds that persons should not be treated merely as a means to others' ends, and this is interpreted to forbid the reduction of the human body to a collection of saleable parts.

This creates a tension with another internationally recognized human right: the **Right to Science**, which includes the right of everyone to enjoy the benefits of scientific progress and the right of creators to the moral and material interests resulting from their scientific productions. An absolute ban on all property interests related to biomedicine could stifle the innovation needed to produce those public benefits.

A sophisticated legal and ethical approach must therefore seek a reconciliation. A plausible path forward involves drawing a line between the human source material and the downstream scientific invention. Such an approach would:
1.  **Prohibit commodification at the source**: Uphold prohibitions on financial gain from the human body and its parts, treating raw tissue and a person's identifiable genome as inalienable with respect to sale. This respects the principles of human dignity and non-instrumentalization.
2.  **Require robust governance**: Mandate strong protections for donors, including prior informed consent, privacy safeguards, and mechanisms for fair benefit-sharing.
3.  **Permit regulated property in inventions**: Allow for regulated intellectual property rights, such as patents, on the downstream *inventions* and curated databases created through scientific labor and ingenuity. This honors the Right to Science by protecting authors' interests and incentivizing research.
4.  **Ensure equitable access**: Make these intellectual property rights subject to public-interest exceptions, such as compulsory or non-exclusive licensing, when necessary to ensure equitable access to essential medical applications.

This balanced model attempts to navigate the difficult terrain between respecting the special status of the human body and promoting the scientific progress that can improve the human condition for all [@problem_id:4501845].